1093

CSPC Pharmaceutical GroupSEHK:1093 Stock Report

Market Cap

HK$113.4b

7D

-0.3%

1Y

-1.9%

Updated

22 Sep, 2021

Data

Company Financials +
1093 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance6/6
Financial Health6/6
Dividends3/6

1093 Overview

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally.

CSPC Pharmaceutical Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CSPC Pharmaceutical Group
Historical stock prices
Current Share PriceHK$9.49
52 Week HighHK$7.08
52 Week LowHK$12.68
Beta0.69
1 Month Change-9.96%
3 Month Change-17.76%
1 Year Change-1.91%
3 Year Change6.43%
5 Year Change132.71%
Change since IPO2,149.48%

Recent News & Updates

Aug 28
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.08

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.08

CSPC Pharmaceutical Group Limited ( HKG:1093 ) has announced that it will be increasing its dividend on the 8th of...

Aug 06
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 40% Below Their Intrinsic Value Estimate

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 40% Below Their Intrinsic Value Estimate

Does the August share price for CSPC Pharmaceutical Group Limited ( HKG:1093 ) reflect what it's really worth? Today...

Jun 26
Do CSPC Pharmaceutical Group's (HKG:1093) Earnings Warrant Your Attention?

Do CSPC Pharmaceutical Group's (HKG:1093) Earnings Warrant Your Attention?

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Shareholder Returns

1093HK PharmaceuticalsHK Market
7D-0.3%-4.4%-4.9%
1Y-1.9%-13.7%5.6%

Return vs Industry: 1093 exceeded the Hong Kong Pharmaceuticals industry which returned -13.7% over the past year.

Return vs Market: 1093 underperformed the Hong Kong Market which returned 5.6% over the past year.

Price Volatility

Is 1093's price volatile compared to industry and market?
1093 volatility
1093 Beta0.69
Industry Beta0.59
Market Beta1

Stable Share Price: 1093 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 1093's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199223,300Dongchen Caihttps://www.cspc.com.hk

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke and memory and mental impairment; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Xuanning for hypertension; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; Enxi to treat adult idiopathic Parkinson’s disease; Keaili for breast cancer; Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; and Encun to prevent atherosclerotic thrombosis events.

Valuation

Is CSPC Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?

45.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1093 (HK$9.49) is trading below our estimate of fair value (HK$17.52)

Significantly Below Fair Value: 1093 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1093 is poor value based on its PE Ratio (15.9x) compared to the Hong Kong Pharmaceuticals industry average (9.7x).

PE vs Market: 1093 is poor value based on its PE Ratio (15.9x) compared to the Hong Kong market (9.8x).


Price to Earnings Growth Ratio

PEG Ratio: 1093 is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: 1093 is overvalued based on its PB Ratio (3.8x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is CSPC Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?

11.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1093's forecast earnings growth (11.8% per year) is above the savings rate (1.5%).

Earnings vs Market: 1093's earnings (11.8% per year) are forecast to grow slower than the Hong Kong market (17.1% per year).

High Growth Earnings: 1093's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1093's revenue (11.5% per year) is forecast to grow slower than the Hong Kong market (12.3% per year).

High Growth Revenue: 1093's revenue (11.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1093's Return on Equity is forecast to be high in 3 years time (20.8%)


Past Performance

How has CSPC Pharmaceutical Group performed over the past 5 years?

24.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1093 has high quality earnings.

Growing Profit Margin: 1093's current net profit margins (22.6%) are higher than last year (17.6%).


Past Earnings Growth Analysis

Earnings Trend: 1093's earnings have grown significantly by 24.4% per year over the past 5 years.

Accelerating Growth: 1093's earnings growth over the past year (42.4%) exceeds its 5-year average (24.4% per year).

Earnings vs Industry: 1093 earnings growth over the past year (42.4%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 1093's Return on Equity (23.7%) is considered high.


Financial Health

How is CSPC Pharmaceutical Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1093's short term assets (CN¥19.1B) exceed its short term liabilities (CN¥6.9B).

Long Term Liabilities: 1093's short term assets (CN¥19.1B) exceed its long term liabilities (CN¥624.4M).


Debt to Equity History and Analysis

Debt Level: 1093 is debt free.

Reducing Debt: 1093 has no debt compared to 5 years ago when its debt to equity ratio was 17.4%.

Debt Coverage: 1093 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1093 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is CSPC Pharmaceutical Group current dividend yield, its reliability and sustainability?

1.78%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1093's dividend (1.78%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.29%).

High Dividend: 1093's dividend (1.78%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.87%).


Stability and Growth of Payments

Stable Dividend: 1093's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1093's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (28.3%), 1093's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 1093's dividends in 3 years are forecast to be well covered by earnings (28.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Dongchen Cai (67 yo)

no data

Tenure

CN¥11,841,000

Compensation

Mr. Dongchen Cai serves as an Executive Chairman and Chief Executive Officer of CSPC Pharmaceutical Group Limited (formerly, China Pharmaceutical Group Limited) and has been its Executive Director since Ap...


CEO Compensation Analysis

Compensation vs Market: Dongchen's total compensation ($USD1.83M) is above average for companies of similar size in the Hong Kong market ($USD1.02M).

Compensation vs Earnings: Dongchen's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1093's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: 1093's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CSPC Pharmaceutical Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: CSPC Pharmaceutical Group Limited
  • Ticker: 1093
  • Exchange: SEHK
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$113.449b
  • Shares outstanding: 11.95b
  • Website: https://www.cspc.com.hk

Number of Employees


Location

  • CSPC Pharmaceutical Group Limited
  • No. 226 Huanghe Street
  • Shijiazhuang
  • Hebei Province
  • 50035
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 10:02
End of Day Share Price2021/09/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.